A review by the U.S. Food and Drug Administration (FDA) has found that the AstraZeneca Plc’s diabetes drug, Onglyza, may be associated with an increased rate of death. A trial was underway of more than 16,000 patients taking Onglyza. It has been reported that these patients had an increased risk of hospital visits due to heart failure. The personal injury attorneys at Williams DeClark Tuschman will continue to monitor this as more news unfolds. In the mean time, should you have any questions regarding Onglyza, please call our office at 419-318-0772. We are more than happy to answer any questions you have.